# The Promoting Resilience in Stress Management (PRISM) Intervention: a multi-site randomized controlled trial for Adolescents and Young Adults receiving Hematopoietic Cell Transplantation

> **NIH NIH R01** · SEATTLE CHILDREN'S HOSPITAL · 2021 · $52,247

## Abstract

PROJECT ABSTRACT
The experience of hematopoietic cell transplantation (HCT) for hematologic malignancy among Adolescents
and Young Adults (AYAs) is particularly difficult because age-related developmental challenges of identity,
relationships, and vocation may add to the burden of cancer. Compared to other age-groups, AYAs have
poorer psychosocial outcomes including increased anxiety and depression and poorer adherence to oral
immunosuppressive medications potentially predisposing AYAS to disease-related morbidity and and/or
cancer-relapse. A potential barrier to improving these experiences may be that AYAs have few opportunities
to develop the personal resources needed to handle adversity. We have previously developed the “Promoting
Resilience in Stress Management” (PRISM) intervention for AYAs with serious illness. This manualized, brief
intervention is delivered in 4, 30-60-minute, one-on-one sessions, followed by a Parent/ Caregiver/ Spouse/
significant other inclusive meeting. It targets skills in stress-management and mindfulness, goal-setting,
positive reframing, and meaning-making. Findings from a phase 2 randomized controlled trial among AYAs
with newly diagnosed cancer demonstrate that PRISM is associated with decreased psychological distress and
increased health-related quality of life. This study will build on our prior experience and fill a critical knowledge
gap regarding PRISM’s impact among AYAs receiving HCT. Thus, we will conduct a multi-site randomized
controlled trial among N=70 AYAs (n=35 PRISM and n=35 usual care; ages 12-24 years), with the primary trial
outcome of patient-reported symptoms of anxiety and depression. We hypothesize that AYAs who receive
PRISM will report fewer mixed affective symptoms, demonstrate better adherence, and show improved
biomedical outcomes, while their parents report improved quality of life and psychological distress. This study
offers an opportunity to expand the body of knowledge regarding methodologically rigorous and evidence-
based psychosocial interventions and standards of care for AYAs with hematologic malignancies and has the
potential to reduce the burden of cancer in these vulnerable populations.
In this proposed diversity supplement, I will contribute to evaluating PRISM’s efficacy in reducing symptoms of
anxiety and depression over the first 6-months post-HCT by assisting with procedure related to recruitment,
data collection, and analysis.

## Key facts

- **NIH application ID:** 10310773
- **Project number:** 3R01CA225629-04S1
- **Recipient organization:** SEATTLE CHILDREN'S HOSPITAL
- **Principal Investigator:** Abby R Rosenberg
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $52,247
- **Award type:** 3
- **Project period:** 2018-04-01 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10310773

## Citation

> US National Institutes of Health, RePORTER application 10310773, The Promoting Resilience in Stress Management (PRISM) Intervention: a multi-site randomized controlled trial for Adolescents and Young Adults receiving Hematopoietic Cell Transplantation (3R01CA225629-04S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10310773. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*